Brainstorm Cell Therapeutics, Inc. BCLI

NAS: BCLI | ISIN: US10501E2019   30/04/2025
1,300 USD (+19,82%)
(+19,82%)   30/04/2025

29 april 2025 · BrainStorm's NurOwn® Data Selected as Breakthrough Science for Presentation at ISCT 2025 Meeting · Persbericht

10 april 2025 · BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn® in ALS · Persbericht

31 maart 2025 · BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update · Persbericht

26 maart 2025 · BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq · Persbericht

24 maart 2025 · BrainStorm to Announce Fourth Quarter and Fiscal Year 2024 Financial Results and Provide a Corporate Update · Persbericht

14 augustus 2024 · BrainStorm Cell Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update · Persbericht

7 augustus 2024 · BrainStorm Cell Therapeutics to Announce Second Quarter Results and Provide a Corporate Update · Persbericht

24 juli 2024 · BCLI Update - Progress Supports Our 10x Plus Value Range Potential · Persbericht

1 juli 2024 · BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program · Persbericht

27 juni 2024 · BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering · Persbericht

26 juni 2024 · BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial · Persbericht

20 juni 2024 · BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer · Persbericht

14 juni 2024 · BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness Expectation · Persbericht

20 mei 2024 · BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn · Persbericht

14 mei 2024 · BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update · Persbericht

17 april 2024 · BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn · Persbericht

11 april 2024 · BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule · Persbericht

10 april 2024 · BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS · Persbericht

9 april 2024 · BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS · Persbericht

8 april 2024 · BrainStorm Cell Therapeutics to Provide Update on NurOwn Program · Persbericht

Mijn selecties